Dr Serena Travaglini is Principal Investigator for the Characterization of leukemic stem cells in FLT3-ITD-positive acute myeloid leukemia
Biography
Serena Travaglini is a Researcher (RTDA) at the Laboratory of Biochemistry and Molecular Biology at University of Rome “Tor Vergata” led by Professor Eleonora Candi. She holds a Master’s degree in Medical Biotechnology and gained an extensive experience in the molecular dynamics of Acute Promyelocytic Leukemia (APL) during her internship in the Neuro-Oncohematology Lab of the Santa Lucia Foundation, supervised by Professor Francesco Lo Coco. Dr. Travaglini pursued her doctoral studies in Medical Biotechnology and Translational Medicine at the Oncohematology Lab at University of Rome “Tor Vergata”. Her doctoral project focused on characterizing FLT3-ITD mutated Leukemia Stem Cells (LSCs) and identifying novel actionable target to prevent disease relapse. During her postdoctoral tenure from 2020 to 2023, Dr. Travaglini conducted research on CD99 as a therapeutic target in FLT3-ITD+ Acute Myeloid Leukemia (AML), exploring its role as a marker for leukemia stem cells and its influence on cell migration and homing in the bone marrow microenvironment. Additionally, she delved into the transcriptomic evolution of Core Binding Factor AML, identifying predictive markers for disease relapse. Currently, as a dedicated Researcher, Dr. Travaglini is exploring the role of p63 in thymoma, contributing to cutting-edge research in the field of medical biotechnology.
Recent publications
Travaglini S, Gurnari C et al. Functional characterization and response to FLT3 inhibitors in acute myeloid leukemia with a non-canonical FLT3 mutation: a proof of concept. Br J Haematol 2023
Ottone T, Silvestrini G, Piazza R, Travaglini S et al. Expression profiling of extramedullary acute myeloid leukemia suggests the involvement of metastasis promoting pathways. Leukemia 2023
Noguera NI*, Travaglini S*, Scalea S et al. YY1 knockdown relieves the differentiation block and restores apoptosis in AML cells. Cancers 2023
Travaglini S, Ottone T, Angelini DF et al. CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML. Leukemia 2022
Travaglini S, Angelini DF, Alfonso V et al. Characterization of FLT3-ITDmut Acute Myeloid Leukemia: molecular profiling of Leukemic Precursor Cells. Blood Cancer J 2020.